Research graph
References from Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries.
10.3322/caac.21660 · 2021 · External reference
Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.
10.1016/j.annonc.2023.11.016 · 2024 · External reference
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
10.1016/s1470-2045(16)00163-7 · 2016 · External reference
Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer.
10.1056/nejmoa1703643 · 2017 · External reference
Adjuvant pertuzumab and trastuzumab in early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up.
10.1200/jco.20.01204 · 2021 · External reference
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
10.1016/s1470-2045(19)30863-0 · 2020 · External reference
Pembrolizumab for early triple-negative breast cancer.
10.1056/nejmoa1910549 · 2020 · External reference
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
10.1016/j.annonc.2024.02.002 · 2024 · External reference
Overall survival with pembrolizumab in early-stage triple-negative breast cancer.
10.1056/nejmoa2409932 · 2024 · External reference
Immunotherapy for HER-2 positive breast cancer.
10.3389/fonc.2023.1097983 · 2023 · External reference
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
10.1093/annonc/mdt133 · 2013 · External reference
HER2-Positive breast cancer immunotherapy: a focus on vaccine development.
10.1007/s00005-019-00566-1 · 2020 · External reference
Vaccination against Her-2/neu, with focus on peptide-based vaccines.
10.1016/j.esmoop.2021.100361 · 2022 · External reference
IgG FC receptors.
10.1146/annurev.immunol.19.1.275 · 2001 · External reference
Trastuzumab–mechanism of action and use in clinical practice.
10.1056/nejmra043186 · 2007 · External reference
Pembrolizumab (Keytruda).
10.1080/21645515.2016.1199310 · 2016 · External reference
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
10.1056/nejmoa052306 · 2005 · External reference
Anti-HER2 cancer therapy and cardiotoxicity.
10.2174/1381612820666140604145037 · 2014 · External reference
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
10.1007/s10549-021-06280-x · 2021 · External reference
Immune-Related adverse events from immune checkpoint inhibitors.
10.1002/cpt.394 · 2016 · External reference
Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy.
10.3389/fphar.2017.00049 · 2017 · External reference
Real-World outcomes with the KEYNOTE-522 regimen in early-stage triple-negative breast cancer.
10.1245/s10434-024-16390-7 · 2025 · External reference
Evaluation of breast surgical oncology complications after single agent versus dual agent HER2 targeted neoadjuvant chemotherapy.
10.1016/j.amjsurg.2020.06.053 · 2020 · External reference
Impact of neoadjuvant chemoimmunotherapy on surgical outcomes and time to radiation in triple-negative breast cancer.
10.1245/s10434-024-15359-w · 2024 · External reference
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer.
10.1007/s12672-024-01349-7 · 2024 · External reference
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.
10.1080/2162402x.2023.2275846 · 2023 · External reference
Surgical outcomes for mastectomy patients receiving neoadjuvant chemotherapy: a propensity-matched analysis.
10.1097/sla.0000000000001804 · 2017 · External reference
Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction.
10.1001/archsurg.2010.163 · 2010 · External reference
Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy.
10.1007/s12282-024-01570-w · 2024 · External reference
A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction.
10.1016/j.breast.2020.11.023 · 2021 · External reference
Cognitive bias and dissonance in surgical practice: a narrative review.
10.1016/j.suc.2022.11.003 · 2023 · External reference
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
10.1097/01.sla.0000133083.54934.ae · 2004 · External reference
The comprehensive complication index: a novel continuous scale to measure surgical morbidity.
10.1097/sla.0b013e318296c732 · 2013 · External reference
Impact of neoadjuvant immunotherapy on postoperative complications in oncoplastic breast cancer surgery.
10.1016/j.ejso.2025.110511 · 2025 · External reference
Real-world evidence of the efficacy of neoadjuvant pembrolizumab in triple-negative breast cancer: a surgeon’s point of view.
10.1016/j.ejso.2025.110011 · 2025 · External reference
Surgical outcomes after neoadjuvant pembrolizumab plus chemotherapy for triple-negative breast cancer: results from the randomized, placebo-controlled phase 3 KEYNOTE-522 study.
10.1245/s10434-026-19121-2 · 2026 · External reference
Adding neoadjuvant immunotherapy to chemotherapy in non-metastatic triple-negative breast cancer: a propensity-matched cohort study from a tertiary cancer center.
10.3390/cancers17243933 · 2025 · External reference
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
10.1001/jama.2013.278932 · 2013 · External reference
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
10.1093/annonc/mdt182 · 2013 · External reference
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
10.1016/s1470-2045(11)70336-9 · 2012 · External reference
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
10.1016/s1470-2045(18)30570-9 · 2018 · External reference
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.
10.1080/1750743x.2026.2662201 · 2026 · External reference
Impact of chemotherapy dose intensity on pathological complete response in pembrolizumab-treated early triple-negative breast cancer: a real-world multicenter analysis.
10.3390/cancers17213554 · 2025 · External reference
Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.
10.1016/j.ejca.2025.116102 · 2026 · External reference
